The IL-2-STAT5 pathway is blocked in chronic lymphocytic leukemia cells by Matveeva, A. et al.
ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ
247ОНКОЛОГИЯ •  Т.  19 •  № 4 •  2017 47
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
common type of leukemias in Europe and USA (about 
30%). The morbidity rate is approximately 3.5 per 
100 000 people (5.0 for men and 2.5 for women in 
USA) [1]. In Ukraine, the disease rate was 3.57/100 000 
in 2016. The predisposition to the disease is often he-
reditary — the risk of developing CLL in immediate 
relatives is 7 fold higher than the median of a popula-
tion [2]. Most of the cases of CLL, if not all, are preced-
ed by the monoclonal B-cell lymphocytosis, which oc-
curs in 5–10% of people over the age of 40 and progress-
es to CLL with a frequency of about 1% per year [2]. The 
ave rage age of men at the time of the disease is 70 years, 
women — 74 years. In people, younger than 50 years 
old, CLL is found very rarely and it was not diagnosed 
in children [3, 4].
CLL is represented by monomorphic small round 
B-lymphocytes with an admixture of pre-B-cells and 
a presence of characteristic pseudo-follicular centers 
of proliferation (revealed by an analysis of histological 
samples) [5]. Diagnosis is usually made on the base of 
infiltration of a bone marrow by clonal population of B-
cells and the high content of B-cells in peripheral blood 
(> 5–10·109) [6].
In spite of long history of CLL study, mechanisms 
of emergence and development of this disease are still 
not fully understood.
One of the hypotheses on the CLL origin is the ac-
cumulation of long-lived immunologically incompe-
tent B-lymphocytes, which divide very rarely (mature 
B-cells) (Fig. 1, a). It was proposed that a proportion 
of CLL cells bearing immunoglobulins variable (IgV) 
region without mutations arise from the mature CD5-
positive B-cells [7]. The heavy-water studies have shown 
that a small subset of the immortal cells is proliferating. 
However, the number of the new cells formed per day is 
very small, ranging from 0.1 to 0.35% of the total num-
ber of cells in the clone [8].
On a surface of CLL cells the CD5, IgM/IgD and 
CD19 antigens were simultaneously detected, that lead to 
a hypothesis that CLL arise from naїve B-cells (Fig. 1, b). 
This was supported by a finding of a post germinal cen-
ter B-cells, expressing the CD5 and CD27 and possess-
ing the mutated IgV. It was concluded, that CLL with 
mutated IgV could be originated from such B-cells [7].
Another possibility is that CLL represents transition-
al B1-cells that are also CD5-positive (Fig. 1, c). B1-cells 
are very poorly characterized. It is known, however, that 
CD5 expression is not a main feature of these cells [9]. 
Recently, it was shown that a subset of the B1-cells can 
produce antibodies [10], in contrast to behavior of CLL 
cells.
It seems that the first hypothesis correctly charac-
terizes CLL cells as the B-cells, incapable to respond to 
different stimuli from the microenvironment (Fig. 1, d). 
At the normal conditions, there is an ideally tuned bal-
ance between stimuli for cells to proliferate and/or un-
dergo apoptosis. Such signals could be transduced via 
B-cell receptor (BCR), expressing on a surface of ma-
ture B-cells, and also by chemokine and cytokine recep-
tors or by direct contact with other cells.
T-cells are among the main players in the CLL mi-
croenvironment. Surprisingly, the different sets of T-cells 
were detected in CLL-patients, compared with healthy 
individuals. Thus, the absolute count of regulatory T-cells 
(Tregs) was dramatically increased in the periphe ral 
blood of CLL patients [11, 12]. Also, the number of help-
er T-cells (Th), especially Th17, was simultaneously de-
creased [13]. One of the main inducers of T-cell activa-
tion and differentiation is interleukin-2 (IL-2) [14, 15]. 
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Of note, the huge increase (up to more than 100 fold) 
of soluble interleukin-2 receptor alpha (sIL-2RA) was 
measured in sera of CLL patients, especially in patients 
with the advance stage of the disease [16].
Fig. 1. A scheme representing a putative origin of CLL cells: a — 
a mature B-cell; b — the memory B-cell; c — the transitional 
B1A cell; d — the typical CLL cell. The scheme was prepared 
with the help of a ChemOffice® Professional 17 free trial copy
We asked a question what is the status of the 
IL-2 pathway in CLL cells, with an aim to understand 
how CLL cells differ from the mature B-cells.
MATERIALS AND METHODS
Clinical specimens
Samples of peripheral blood of CLL patients were ob-
tained at the R.E. Kavetsky Institute of Experimental Pa-
thology, Oncology and Radiobiology (IEPOR) of NAS 
of Ukraine (from 19.11.2014 till 31.12.2016). The study in-
cluded 29 patients with B-cell CLL diagnoses. The main 
types and cytological variants of diseases were diagnosed, 
according to the WHO classification [17]. For control, B-
cells were isolated from the peripheral blood of 3 healthy 
donors. All experimental work was performed, according 
to protocols, approved by the Committee on Bio ethics at 
R.E. Kavetsky IEPOR.
RNA isolation and c-DNA synthesis
CLL cells were isolated from the peripheral blood 
by Ficoll-Paque gradient centrifugation, resuspend-
ed in TRIzol reagent (Gibco BRL, USA) and stored at 
−20 °C until further use. The total RNA was isolated, us-
ing the RNeasy Mini Kit (Qiagen Inc., Germany), ac-
cording to the manufacturer’s instructions. The cDNAs 
were synthesized, using M-MLV Reverse Transcriptase 
and RNAse inhibitor (Invitrogen, USA), according to 
the manufacturer’s protocol. 2 μg of total RNA was used 
for cDNA synthesis.
Analysis of transcription factors expression, using 
RT2 profiler assay
The expression profile of 84 transcription factors 
was studied, along with 12 positive and negative con-
trols (a total of 96 genes) on two identical PARN-075Z 
plates. The RNA mixture consisted of 25 μl (a half) of 
each RNA solution, isolated from the samples. The con-
trol group was a mixture of RNA, isolated from periph-
eral blood B-cells of 3 healthy donors. q-PCR was per-
formed, using 2 μg cDNA and the SYBR Green Master 
Mix (Thermo Fisher Scientific Inc., USA) on PCR Sys-
tem 7500 (Applied Biosystem, USA). CT was not mea-
sured after 35 cycles. The obtained CT values were down-
loaded to the manufacturer’s website (Thermo Fisher 
Scientific Inc., USA) for online analysis of expression 
of transcription factors.
Bioinformatic data analysis
In order to analyze expression of genes at a mRNA 
level, several publically available databases were used: 
the GTEx Portal (http://www.gtexportal.org/home); 
the Broad-Novartis CCLE (Cancer cell line encyclope-
dia) portal at the Broad Institute website (https://por-
tals.broadinstitute.org/ccle); the Oncomine, which con-
tains published data that has been collected, standard-
ized, annotated and analyzed by Compendia Bioscience 
(www.oncomine.com, September 2017, Thermo Fisher 
Scientific, Ann-Arbor, MI, USA).
RESULTS AND DISCUSSION
Expression of 84 transcription factors was studied, 
using the PARN-075Z platform. To reveal the dif-
ferences of gene expression in cells of CLL patients, 
a mixture of RNA isolated from the periphe ral blood 
B-cells of 29 CLL patients and RNA samples from 
three healthy donors was used. Only few genes were ex-
pressed at a higher level in CLL cells compared with B 
cells of healthy donors, namely, POU2, ATF1, NFAT5, 
NFATC1, JUNB, JUN, and RELB (see also our earlier 
publication [18]). We have found that seve ral genes, 
stimulating proliferation, such as MYC and NFkB1, 
were downregulated (3.26 and 4.23 fold, respectively) 
in CLL cells. This corresponds to the nature of CLL 
cells, which do not show a proliferative activity. Not 
only MYC, but also ID1 and HIF1A trans cription fac-
tors expressed at very low levels in CLL cells (Fig. 2, 
a). To validate our results, an analysis of the open pub-
licly available data bases was performed. Thus, we have 
found that the ID1 gene was downregulated in CLL, 
compared with peripheral blood B-cells of the healthy 
donors (Fig. 2, b, c). Results presented in Fig. 2, b, c 
were obtained by analysis of the data at the Oncomine 
portal [19] and [20], respectively. The same trend was 
shown by the MYC gene (Fig. 2, d, e), as was shown 
by a study on various tumor types and lymphomas [19] 
and [21], respectively.
Noteworthy, all the above-mentioned genes — 
HIF1A, ID1 and MYC — are responsive genes of an IL-2 
induced JAK-STAT5 signaling pathway [22]. Therefore, 
next we have analyzed expression of other STAT5-re-
sponsive genes, namely MCL1, BCL2, BCL-XL, Cyclin 
D2 (CCND2), and Cyclin D1 and cyclin-dependent ki-
nase inhibitors p21 (CDKN1A) and p16 (CDKN2A) as 
controls.
Expression of the MCL1 gene was down-regu-
lated (Fig. 2, f, according to [20]), as well as BCL2 
(Fig. 3, a), BCL-XL (Fig. 3, b) and Cyclin D2 (Fig. 3, f). 
Noteworthy, expression levels of p16, p21 and Cy-
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clin D1 have not changed at the same time (Fig. 3, c, 
d, e, respectively).
Next question was asked, what is the status of STAT 
genes in CLL cells of a studied cohort of patients. We 
have found, that expression of STAT genes was not al-
tered, except for up-regulation of STAT2 and STAT5A 
and dramatic down-regulation of STAT4 (Fig. 4, a). 
Noteworthy, similar trend for STAT5A and STAT5B 
was reported earlier by [20] (Fig. 4, b, c). Important-
ly, mRNA levels of STAT5A and STAT5B are quite high 
in many lymphoid organs and in tumor cell lines of B-
cell origin (Fig. 5).
Taking into consideration, that STAT proteins func-
tion as transcription factors only as heterodimers of phos-
phorylated proteins [22], the down-regulation of the re-
sponsive genes could be due to lack of phosphorylation, 
absence of IL-2RA expression, or no IL-2 in the pe-
ripheral blood.
In order to monitor the levels of IL-2RA mRNA, we 
analyzed the publicly available databases. IL-2RA expres-
sion was quite high in many lymphoid tumors, as well as 
in lymphoid organs and blood (Fig. 6, a, b). Moreover, 
CLL cells and peripheral blood B-cells de monstrated 
similar IL-2RA expression (Fig. 6, c, d).
As was mentioned above, in the serum of CLL pa-
tient the concentration of soluble IL-2RA was 100 fold 
higher, compared to the blood of healthy individu-
als [16]. It is reasonable to conclude, that even a spe-
cial set of T-cell secrets IL-2, this cytokine is inacti-
vated by sIL-2RA, and CLL cells do not get a signal 
to differentiate into plasma cells, or antibody produc-
ing cells. Therefore, we propose that inactivation of the 
JAK-STAT5 pathway might be due to lack of free IL-2 
(Fig. 7), or due to inability of STAT proteins to become 
phosphorylated and form heterodimers. The latter will 
be a subject of our future work.
CONCLUSIONS
We have found that the JAK-STAT5 pathway is large-
ly inactivated in CLL cells. Despite elevated expression 
of STAT2 and STAT5 genes at the mRNA level, STAT5-
responsive genes, such as BCL2L1 (BCL-XL), CCND2 
Fig. 2. Expression levels of STAT5-responsive genes: a — relative expression at the mRNA level, assessed by q-PCR; b — the 
ID1 gene expression at the mRNA levels, assessed by microarray technique [19]; c — the ID1 gene expression at the mRNA levels, 
assessed by microarray technique [20]; d — the MYC gene expression at the mRNA levels, assessed by microarray technique [19]; 
e — the MYC gene expression at the mRNA levels, assessed by microarray technique [21]; f — the MCL1 gene expression at the 
mRNA levels, assessed by microarray technique [20]
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Fig. 3. Expression levels of BCL2 (a), CDKN2A (c), CDKN1A (d), CCND1 (e) and STAT5-responsive genes BCL2L1 (b) 
and CCND2 (f), assessed by microarray technique [20]. Notice the significant down-regulation of STAT5-responsive genes, 
BCL2L1 and CCND2
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Fig. 4. Relative expression levels of STAT genes at the mRNA level, assessed by q-PCR (a). STAT5A (b) and STAT5B (c) expressed 
at the similar levels in CLL cells and B-lymphocytes, as was shown by the microarray technique [20]
Fig. 5. Relative expression levels of STAT5A (Entrez Gene ID: 6776) (a) and (b) and STAT5B (Entrez Gene ID: 6777) (c) and (d) 
genes at the mRNA level. An analysis of expression in B-cell originated tumor cell lines (indicated with arrows on (a) and (c)) was 
performed on September 15th, 2017 at https://portals.broadinstitute.org/ccle. RMA — Robust multichip averaging, relative units of 
the signal intensity. Noteworthy, the high levels of the STAT5A were detected in whole blood and spleen, as well as in EBV-trans-
formed B-lymphocytes (indicated with arrows on (b)), as was assessed on September 15th, 2017 at http://www.gtexportal.org/home. 
Simultaneously, the highest levels of STAT5B were detected in whole blood (indicated with arrows on (d)). RPKM — read per ki-
lobase per million mapped reads, normalized to the gene length
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(Cyclin D2), HIF1A, ID1, MCL1, and MYC are down-
regulated in CLL-cells, compared to peripheral blood 
B-cells of healthy individuals.
The inactivation of the JAK-STAT5 pathway could be 
explained by the high levels of soluble IL-2RA, as was 
reported earlier. Another possibility could be inhibition 
of STAT5 phosphorylation, leading to inability to form 
the active transcriptionally protein heterodimers. The 
phosphorylation status of STAT proteins in CLL cells 
should be further illuminated.
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СИГНАЛЬНИЙ ШЛЯХ IL-2-STAT5 
ЗАБЛОКОВАНО У КЛІТИНАХ 
ХРОНІЧНОГО ЛІМФОЛЕЙКОЗУ
А. Матвєєва, Л. Ковалевська, А. Поліщук, 
О. Кашуба
Резюме. Мета: вивчити стан шляху інтерлейкі-
ну-2 (IL-2) у клітинах хронічного лімфоцитарно-
го лейкозу (ХЛЛ), щоб зрозуміти функціональні від-
мінності між ХЛЛ і зрілими B-клітинами. Об’єкти 
і методи: зразки периферичної крові хворих на ХЛЛ, 
ізоляція РНК, аналіз експресії транс крипційних 
факторів із використанням аналізу плати RT2 
та кількісної полімеразної ланцюгової реакції, біо-
інформатичний аналіз загальнодоступних баз да-
них щодо експресії генів. Результати: виявлено, 
що сигнальний шлях JAK-STAT5 переважно інак-
тивований в клітинах ХЛЛ. Незважаючи на під-
вищену експресію генів STAT2 та STAT5 на рівні 
мРНК у клітинах ХЛЛ експресія генів, які трансак-
тивуються STAT5, таких як BCL2L1 (BCL-XL), 
CCND2 (циклін D2), HIF1A, ID1, MCL1 та MYC, 
знижена порівняно з цим показником у В-клітинах 
периферичної крові здорових донорів. Висновки: 
інактивація шляху JAK-STAT5 може бути пояс-
нена високим рівнем розчинного IL-2RA, як було 
показано раніше. Також є можливим інгібуван-
ня фосфорилювання протеїну STAT5, що робить 
неможливим утворення гетеродимерів білків, які 
є транскрипційно активними. Стан фосфорилю-
вання білків STAT у клітинах ХЛЛ потребує до-
даткового вивчення.
Ключові слова: В-клітинний хронічний 
лімфоцитарний лейкоз (ХЛЛ), інтерлейкін-2 
(IL-2), CD25, STAT, фактори транскрипції, 
шлях IL-2-STAT5.
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Fig. 7. A schematic view on an IL-2-STAT5 pathway. The IL-2 
molecule binds to IL-2R, and JAKs kinases are phosphorylat-
ed. Then, JAKs phosphorylate STAT proteins, which can form 
heterodimers. These heterodimers bind to a speci fic DNA se-
quence and activate transcription of the responsive genes. 
A set of STAT5 responsive genes (BCL2L1, MYC, ID1, MCL1, 
CCND2) showed diminished expression, despite high expres-
sion of STAT5A and STAT5B in CLL cells, compared with pe-
ripheral blood B-cells. This might be due to lack of STAT and/
or JAK phosphorylation, or low concentration of available IL-2 
in serum of CLL patients. The scheme was prepared with the 
help of a ChemOffice® Professional 17 free trial copy
